$6.92
3.22% yesterday
Nasdaq, Jun 13, 10:02 pm CET
ISIN
US02155H1014
Symbol
ALT

Altimmune, Inc. Stock price

$6.92
+1.16 20.14% 1M
-2.11 23.37% 6M
-0.29 4.02% YTD
+0.31 4.69% 1Y
-0.76 9.90% 5Y
-10.38 60.00% 10Y
-62.98 90.10% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.23 3.22%
ISIN
US02155H1014
Symbol
ALT
Sector
Industry

Key metrics

Market capitalization $579.91m
Enterprise Value $430.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 21,504.25
P/S ratio (TTM) P/S ratio 28,995.75
P/B ratio (TTM) P/B ratio 3.91
Revenue growth (TTM) Revenue growth -95.12%
Revenue (TTM) Revenue $20.00k
EBIT (operating result TTM) EBIT $-98.19m
Free Cash Flow (TTM) Free Cash Flow $-80.33m
Cash position $149.83m
EPS (TTM) EPS $-1.19
P/E forward negative
P/S forward 110,459.05
EV/Sales forward 81,920.00
Short interest 27.31%
Show more

Is Altimmune, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Altimmune, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Altimmune, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Altimmune, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Altimmune, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.02 0.02
95% 95%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
14% 14%
108,250%
- Research and Development Expense 77 77
9% 9%
382,850%
-98 -98
2% 2%
-490,150%
- Depreciation and Amortization 0.16 0.16
72% 72%
800%
EBIT (Operating Income) EBIT -98 -98
3% 3%
-490,965%
Net Profit -90 -90
3% 3%
-451,200%

In millions USD.

Don't miss a Thing! We will send you all news about Altimmune, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altimmune, Inc. Stock News

Neutral
GlobeNewsWire
about 14 hours ago
GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association's (ADA) 85th Scientific Sessions, to be held in Chicago, IL f...
Positive
Seeking Alpha
11 days ago
I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in multiple metabolic diseases, making it an attractive acquisition target. VKTX's VK2735 offers strong weight loss efficacy and dual formulation flexibility, but faces tough competition and lacks cle...
Positive
Seeking Alpha
15 days ago
ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, although pemvidutide will be compared to other competitors. ALT has also initiated a trial of pemvidutide in alcohol use disorder, with a trial in alcohol liver disease set to start in Q3'25.
More Altimmune, Inc. News

Company Profile

Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Vipin Garg
Employees 59
Founded 1997
Website altimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today